This is what I’d do about GlaxoSmithKline’s big 5% dividend yield right now
The Motley Fool
Published Feb 17, 2019 10:30
I’ve lost count of how many shares I’ve rejected for my long-term income portfolio, but it’s a lot! It doesn’t matter whether they were small-caps, mid-caps or great big well-known FTSE 100 companies, they’ve all gone the same way – out the window as far as I’m concerned.
Of course, I’ve considered them in the first place because they’ve all had a large dividend yield, or perhaps an average yield but with a dividend that has been growing at an impressive annual rate. But, for me, big and growing yields are not enough on their own. I want ‘quality’ dividends, which means they must be sustainable.
The search for quality I skip most cyclical firms. The trouble with cyclicals, as I see it, is that they often go in disguise as big-dividend-payers, but they fail the test of sustainability. Look at the fat yields available from companies such as housebuilder Persimmon (LON:PSN), banker Lloyds Banking Group (LON:LLOY) and miner Rio Tinto (LON:RIO). At first glance, those firms look tempting for an income portfolio with their big payouts and low valuations.
But I think cyclical firms with low valuations following a period of strong profits are dangerous. In the next cyclical down-leg, they can be vulnerable to the collapse of their profits, share prices and dividends. In other words, they look their most attractive when they are at their most dangerous. What’s the point of collecting the dividend now when there’s a risk that a share price plunge down the road could wipe out my income gains?
Dividends can also be at risk because of weak business models. I reckon it’s important that a big or growing dividend is backed up with an underlying business that scores well against quality indicators, which would suggest that the company is trading in a strong and profitable niche of the market.
Quality and forward-looking opportunity One company that I’m happy to add to my income portfolio is pharmaceutical giant GlaxoSmithKline (LSE: GSK). The dividend yield runs just above 5%, which looks attractive, although I admit it’s not perfect because the dividend has been flat for a few years and I’d prefer to see the payment rising a little annually.
Get The App
Nevertheless, the company operates in a defensive sector and I see defensive businesses as operating at the opposite end of the scale from cyclical businesses. Whereas the cyclicals tend to see their profits rise and fall along with the undulations of the wider economy, defensives tend to enjoy stable incoming cash flow and profits because of evergreen demand for their products and services. As such, a defensive business is often well placed to support its dividend payments over the long haul. I think the pharmaceutical sector is fertile ground for finding decent dividend-paying firms, because customers tend to keep buying medicines whatever the general economic weather.
Indeed, GlaxoSmithKline has a recent news of the firm’s plans to combine its consumer health businesses with that of Pfizer (NYSE:PFE) in a new joint venture could unlock value. Overall, I see the shares as attractive and would be happy to add them to my income portfolio today.
Kevin Godbold has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
Motley Fool UK 2019
Written By: The Motley Fool
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.